JNJ

230.64

+1.43%↑

ISRG

496

-1.52%↓

ABT

109.39

+0.15%↑

RDY

13.59

+1.42%↑

NEOG

10.23

+0.2%↑

JNJ

230.64

+1.43%↑

ISRG

496

-1.52%↓

ABT

109.39

+0.15%↑

RDY

13.59

+1.42%↑

NEOG

10.23

+0.2%↑

JNJ

230.64

+1.43%↑

ISRG

496

-1.52%↓

ABT

109.39

+0.15%↑

RDY

13.59

+1.42%↑

NEOG

10.23

+0.2%↑

JNJ

230.64

+1.43%↑

ISRG

496

-1.52%↓

ABT

109.39

+0.15%↑

RDY

13.59

+1.42%↑

NEOG

10.23

+0.2%↑

JNJ

230.64

+1.43%↑

ISRG

496

-1.52%↓

ABT

109.39

+0.15%↑

RDY

13.59

+1.42%↑

NEOG

10.23

+0.2%↑

Home・Aandelen Lijst・Celldex Therapeutics Inc

Celldex Therapeutics Inc

Gesloten

SectorGezondheidszorg

24.55

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

24.24

Max

25.04

Belangrijke statistieken
By Trading Economics
Inkomsten	-10M -67M
Winstmarge	-7,753.425
Werknemers	186
EBITDA	-9.8M -73M

Aanbevelingen
By TipRanks
Aanbevelingen	Strong Buy
12 Maanden Prognose	+117.48% upside

Dividenden
By Dow Jones
Volgende Winsten	25 feb 2026

Marktinformatie
By TradingEconomics
Marktkapitalisatie	260M 1.8B
Vorige openingsprijs	24.55
Vorige sluitingsprijs	24.55

Nieuwssentiment

By Acuity

50%

147 / 352 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Weak Bullish Evidence

18.91 / 20.63 Steun & Weerstand

Celldex Therapeutics Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

2 feb 2026, 23:52 UTC

Acquisities, Fusies, Overnames

Elliott Management Doesn't Plan to Tender Its Shares at the Current Terms

2 feb 2026, 23:52 UTC

Acquisities, Fusies, Overnames

Elliott Management: Toyota Fudosan Revised Tender Offer for Toyota Industries 'Very Significantly Undervalues' Company

2 feb 2026, 23:48 UTC

Marktinformatie

Nikkei May Rise on Signs of U.S. Economic Strength -- Market Talk

2 feb 2026, 23:38 UTC

Marktinformatie

Gold Rises on Likely Technical Recovery, Dip-Buying Interest -- Market Talk

2 feb 2026, 23:28 UTC

Marktinformatie

SpaceX, xAI Deal Further Consolidates Musk's Businesses -- Market Talk

2 feb 2026, 23:23 UTC

Winsten

Palantir Achieves Another Revenue Record With $1.41 Billion Quarter -- 2nd Update

2 feb 2026, 22:57 UTC

Winsten

Palantir Reports Strong Earnings. The Stock Is Rising. -- Barrons.com

2 feb 2026, 22:22 UTC

Acquisities, Fusies, Overnames

What the Blockbuster SpaceX--xAI Merger Can Mean for Tesla Stock -- Barrons.com

2 feb 2026, 22:08 UTC

Marktinformatie

Australian Inflation Woes Rooted In Excess Govt Spending -- Market Talk

2 feb 2026, 21:51 UTC

Winsten

Palantir Reports Strong Earnings. The Stock Is Rising. -- Barrons.com

2 feb 2026, 21:50 UTC

Marktinformatie

Basic Materials Roundup: Market Talk

2 feb 2026, 21:49 UTC

Winsten

Disney's Streaming Profit Surges as CEO Decision Approaches -- 5th Update

2 feb 2026, 21:39 UTC

Winsten

Palantir Reports Strong Earnings. The Stock Is Rising. -- Barrons.com

2 feb 2026, 21:36 UTC

Winsten

Palantir Achieves Another Revenue Record With $1.41 Billion Quarter -- Update

2 feb 2026, 21:34 UTC

Winsten

Palantir Reports Strong Earnings. The Stock Is Rising. -- Barrons.com

2 feb 2026, 21:28 UTC

Acquisities, Fusies, Overnames

What a SpaceX--xAI Merger Could Mean for Tesla Stock -- Barrons.com

2 feb 2026, 21:23 UTC

Winsten

BYD, Chinese EV Stock Plunge On Weak Data. What That Means for Tesla Stock. -- Barrons.com

2 feb 2026, 21:19 UTC

Winsten

Palantir Technologies: U.S. Commercial Business Growing at 'Astonishing' Rate, Generating $507 Million Last Quarter, 137% Increase Over the Same Period the Year Before >PLTR

2 feb 2026, 21:17 UTC

Winsten

Palantir Achieves Another Revenue Record With $1.41 Billion Quarter -- WSJ

2 feb 2026, 21:17 UTC

Winsten

Palantir Reports Strong Earnings. The Stock Is Rising. -- Barrons.com

2 feb 2026, 21:10 UTC

Winsten

Palantir Reports Strong Earnings. The Stock Is Rising. -- Barrons.com

2 feb 2026, 21:08 UTC

Winsten

Palantir Technologies: Rule of 40 Score Is Now 127% >PLTR

2 feb 2026, 21:07 UTC

Winsten

Palantir Technologies: Sees 2026 U.S. Comml Rev in Excess of $3.144B, Representing Growth Rate of at Least 115% >PLTR

2 feb 2026, 21:05 UTC

Winsten

Palantir Technologies 4Q Net $608.7M >PLTR

2 feb 2026, 21:05 UTC

Winsten

Palantir Technologies 4Q Rev $1.41B >PLTR

2 feb 2026, 21:05 UTC

Winsten

Palantir Technologies Sees 1Q Rev $1.53B-$1.54B >PLTR

2 feb 2026, 21:05 UTC

Winsten

Palantir Technologies Sees FY Rev $7.18B-$7.2B >PLTR

2 feb 2026, 21:05 UTC

Winsten

Palantir Technologies 4Q Adj EPS 25c >PLTR

2 feb 2026, 21:05 UTC

Winsten

Palantir Technologies 4Q EPS 24c >PLTR

2 feb 2026, 20:40 UTC

Marktinformatie

Treasury Yields, Dollar Rise Amid Signs of Resilient U.S. Economy -- Market Talk

Peer Vergelijking

Prijswijziging

Celldex Therapeutics Inc Prognose

Koersdoel

By TipRanks

117.48% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 53.5 USD 117.48%

Hoogste 90 USD

Laagste 24 USD

Gebaseerd op 9 Wall Street-analisten die 12-maands prijsdoelen bieden voor Celldex Therapeutics Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

9 ratings

Buy

Hold

Sell

Gebaseerd op 9 analisten die aandelenratings hebben gegeven aan Celldex Therapeutics Inc - Dist in de afgelopen 3 maanden.

Technische score

By Trading Central

18.91 / 20.63Steun & Weerstand

Recent bullish events outweigh bearish events.

All events are bearish.

Sentiment

By Acuity

147 / 352 Rangschikking in Gezondheidszorg

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

Over Celldex Therapeutics Inc

Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases. The company's clinical development programs CDX-0159, a Phase II monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity. It has research collaboration and license agreements with Yale University. The company was incorporated in 1983 and is headquartered in Hampton, New Jersey.